Cladribine inhibits secretion of pro-inflammatory cytokines and phagocytosis in human monocyte-derived M1 macrophages in-vitro
- 1 February 2021
- journal article
- research article
- Published by Elsevier in International Immunopharmacology
- Vol. 91, 107270
Abstract
No abstract availableKeywords
Funding Information
- Merck KGaA
- Merck
This publication has 15 references indexed in Scilit:
- Cladribine exerts an immunomodulatory effect on human and murine dendritic cellsInternational Immunopharmacology, 2014
- Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosisJournal of Neuroimmunology, 2013
- Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosisJournal of the Neurological Sciences, 2013
- 2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cellsClinical and Experimental Immunology, 2013
- Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat MicrogliaJournal of Neuroimmune Pharmacology, 2012
- Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptorsNaunyn-Schmiedeberg's Archives of Pharmacology, 2012
- Adenosine: An endogenous modulator of innate immune system with therapeutic potentialEuropean Journal of Pharmacology, 2009
- Multiple sclerosis: Distribution of inflammatory cells in newly forming lesionsAnnals of Neurology, 2009
- The Clinical Pharmacokinetics of CladribineClinical Pharmacokinetics, 1997
- 2-Chlorodeoxyadenosine-Induced Complete Remissions in Langerhans-Cell HistiocytosisAnnals of Internal Medicine, 1994